Algorithm development for corticosteroid management in systemic juvenile idiopathic arthritis trial using consensus methodology

Norman T. Ilowite; Christy I. Sandborg; Brian M. Feldman; Alexi Grom; Laura E. Schanberg; Edward H. Giannini; Carol A. Wallace; Rayfel Schneider; Kathleen Kenney; Beth Gottlieb; Philip J. Hashkes; Lisa Imundo; Yukiko Kimura; Bianca Lang; Michael Miller; Diana Milojevic; Kathleen M. O'Neil; Marilynn Punaro; Natasha Ruth; Nora G. Singer; Richard K. Vehe; James Verbsky; Amy Woodward; Lawrence Zemel

doi:10.1186/1546-0096-10-31

Algorithm development for corticosteroid management in systemic juvenile idiopathic arthritis trial using consensus methodology

Norman T. Ilowite, Christy I. Sandborg, Brian M. Feldman, Alexi Grom, Laura E. Schanberg, Edward H. Giannini, Carol A. Wallace, Rayfel Schneider, Kathleen Kenney, Beth Gottlieb, Philip J. Hashkes, Lisa Imundo, Yukiko Kimura, Bianca Lang, Michael Miller, Diana Milojevic, Kathleen M. O'Neil, Marilynn Punaro, Natasha Ruth, Nora G. SingerRichard K. Vehe, James Verbsky, Amy Woodward, Lawrence Zemel

Pediatric Rheumatology, Allergy & Immunology

Research output: Contribution to journal › Article › peer-review

16 Scopus citations

Abstract

Background: The management of background corticosteroid therapy in rheumatology clinical trials poses a major challenge. We describe the consensus methodology used to design an algorithm to standardize changes in corticosteroid dosing during the Randomized Placebo Phase Study of Rilonacept in Systemic Juvenile Idiopathic Arthritis Trial (RAPPORT).Methods: The 20 RAPPORT site principal investigators (PIs) and 4 topic specialists constituted an expert panel that participated in the consensus process. The panel used a modified Delphi Method consisting of an on-line questionnaire, followed by a one day face-to-face consensus conference. Consensus was defined as ≥ 75% agreement. For items deemed essential but when consensus on critical values was not achieved, simple majority vote drove the final decision.Results: The panel identified criteria for initiating or increasing corticosteroids. These included the presence or development of anemia, myocarditis, pericarditis, pleuritis, peritonitis, and either complete or incomplete macrophage activation syndrome (MAS). The panel also identified criteria for tapering corticosteroids which included absence of fever for ≥ 3 days in the previous week, absence of poor physical functioning, and seven laboratory criteria. A tapering schedule was also defined.Conclusion: The expert panel established consensus regarding corticosteroid management and an algorithm for steroid dosing that was well accepted and used by RAPPORT investigators. Developed specifically for the RAPPORT trial, further study of the algorithm is needed before recommendation for more general clinical use.

Original language	English (US)
Article number	31
Journal	Pediatric Rheumatology
Volume	10
DOIs	https://doi.org/10.1186/1546-0096-10-31
State	Published - Aug 29 2012

Bibliographical note

Funding Information:
Supported by a grant from the National Institute of Arthritis, Musculoskeletal and Skin Diseases (NO1 AR 700015) (ClinicalTrials.gov identifier NCT00534495) and by the Arthritis Foundation. B Feldman declares that he is on the Data Safety and Monitoring Boards for drugs from Novartis, Pfizer, and Bristol Myers Squibb, and has research support from Baxter Labs and Bayer.

Funding Information:
standardize changes in corticosteroid dosing during the study. RAPPORT is a study of the efficacy and short-term safety of the IL-1 inhibitor rilonacept in systemic JIA (SJIA), which utilized 20 sites from the Childhood Arthritis and Rheumatology Research Alliance (CARRA), and was funded by the National Institute of Arthritis, Musculoskeletal and Skin Diseases (NO1 AR 700015).

Publisher link

10.1186/1546-0096-10-31

Find It

Find It at U of M Libraries

Cite this

Ilowite, N. T., Sandborg, C. I., Feldman, B. M., Grom, A., Schanberg, L. E., Giannini, E. H., Wallace, C. A., Schneider, R., Kenney, K., Gottlieb, B., Hashkes, P. J., Imundo, L., Kimura, Y., Lang, B., Miller, M., Milojevic, D., O'Neil, K. M., Punaro, M., Ruth, N., ... Zemel, L. (2012). Algorithm development for corticosteroid management in systemic juvenile idiopathic arthritis trial using consensus methodology. Pediatric Rheumatology, 10, [31]. https://doi.org/10.1186/1546-0096-10-31

Ilowite, NT, Sandborg, CI, Feldman, BM, Grom, A, Schanberg, LE, Giannini, EH, Wallace, CA, Schneider, R, Kenney, K, Gottlieb, B, Hashkes, PJ, Imundo, L, Kimura, Y, Lang, B, Miller, M, Milojevic, D, O'Neil, KM, Punaro, M, Ruth, N, Singer, NG, Vehe, RK, Verbsky, J, Woodward, A & Zemel, L 2012, 'Algorithm development for corticosteroid management in systemic juvenile idiopathic arthritis trial using consensus methodology', Pediatric Rheumatology, vol. 10, 31. https://doi.org/10.1186/1546-0096-10-31

@article{c6f2e0e06fcd48079118ef7f14aaae71,

title = "Algorithm development for corticosteroid management in systemic juvenile idiopathic arthritis trial using consensus methodology",

abstract = "Background: The management of background corticosteroid therapy in rheumatology clinical trials poses a major challenge. We describe the consensus methodology used to design an algorithm to standardize changes in corticosteroid dosing during the Randomized Placebo Phase Study of Rilonacept in Systemic Juvenile Idiopathic Arthritis Trial (RAPPORT).Methods: The 20 RAPPORT site principal investigators (PIs) and 4 topic specialists constituted an expert panel that participated in the consensus process. The panel used a modified Delphi Method consisting of an on-line questionnaire, followed by a one day face-to-face consensus conference. Consensus was defined as ≥ 75% agreement. For items deemed essential but when consensus on critical values was not achieved, simple majority vote drove the final decision.Results: The panel identified criteria for initiating or increasing corticosteroids. These included the presence or development of anemia, myocarditis, pericarditis, pleuritis, peritonitis, and either complete or incomplete macrophage activation syndrome (MAS). The panel also identified criteria for tapering corticosteroids which included absence of fever for ≥ 3 days in the previous week, absence of poor physical functioning, and seven laboratory criteria. A tapering schedule was also defined.Conclusion: The expert panel established consensus regarding corticosteroid management and an algorithm for steroid dosing that was well accepted and used by RAPPORT investigators. Developed specifically for the RAPPORT trial, further study of the algorithm is needed before recommendation for more general clinical use.",

author = "Ilowite, {Norman T.} and Sandborg, {Christy I.} and Feldman, {Brian M.} and Alexi Grom and Schanberg, {Laura E.} and Giannini, {Edward H.} and Wallace, {Carol A.} and Rayfel Schneider and Kathleen Kenney and Beth Gottlieb and Hashkes, {Philip J.} and Lisa Imundo and Yukiko Kimura and Bianca Lang and Michael Miller and Diana Milojevic and O'Neil, {Kathleen M.} and Marilynn Punaro and Natasha Ruth and Singer, {Nora G.} and Vehe, {Richard K.} and James Verbsky and Amy Woodward and Lawrence Zemel",

note = "Funding Information: Supported by a grant from the National Institute of Arthritis, Musculoskeletal and Skin Diseases (NO1 AR 700015) (ClinicalTrials.gov identifier NCT00534495) and by the Arthritis Foundation. B Feldman declares that he is on the Data Safety and Monitoring Boards for drugs from Novartis, Pfizer, and Bristol Myers Squibb, and has research support from Baxter Labs and Bayer. Funding Information: standardize changes in corticosteroid dosing during the study. RAPPORT is a study of the efficacy and short-term safety of the IL-1 inhibitor rilonacept in systemic JIA (SJIA), which utilized 20 sites from the Childhood Arthritis and Rheumatology Research Alliance (CARRA), and was funded by the National Institute of Arthritis, Musculoskeletal and Skin Diseases (NO1 AR 700015).",

year = "2012",

month = aug,

day = "29",

doi = "10.1186/1546-0096-10-31",

language = "English (US)",

volume = "10",

journal = "Pediatric Rheumatology",

issn = "1546-0096",

publisher = "BioMed Central",

}

TY - JOUR

T1 - Algorithm development for corticosteroid management in systemic juvenile idiopathic arthritis trial using consensus methodology

AU - Ilowite, Norman T.

AU - Sandborg, Christy I.

AU - Feldman, Brian M.

AU - Grom, Alexi

AU - Schanberg, Laura E.

AU - Giannini, Edward H.

AU - Wallace, Carol A.

AU - Schneider, Rayfel

AU - Kenney, Kathleen

AU - Gottlieb, Beth

AU - Hashkes, Philip J.

AU - Imundo, Lisa

AU - Kimura, Yukiko

AU - Lang, Bianca

AU - Miller, Michael

AU - Milojevic, Diana

AU - O'Neil, Kathleen M.

AU - Punaro, Marilynn

AU - Ruth, Natasha

AU - Singer, Nora G.

AU - Vehe, Richard K.

AU - Verbsky, James

AU - Woodward, Amy

AU - Zemel, Lawrence

N1 - Funding Information: Supported by a grant from the National Institute of Arthritis, Musculoskeletal and Skin Diseases (NO1 AR 700015) (ClinicalTrials.gov identifier NCT00534495) and by the Arthritis Foundation. B Feldman declares that he is on the Data Safety and Monitoring Boards for drugs from Novartis, Pfizer, and Bristol Myers Squibb, and has research support from Baxter Labs and Bayer. Funding Information: standardize changes in corticosteroid dosing during the study. RAPPORT is a study of the efficacy and short-term safety of the IL-1 inhibitor rilonacept in systemic JIA (SJIA), which utilized 20 sites from the Childhood Arthritis and Rheumatology Research Alliance (CARRA), and was funded by the National Institute of Arthritis, Musculoskeletal and Skin Diseases (NO1 AR 700015).

PY - 2012/8/29

Y1 - 2012/8/29

N2 - Background: The management of background corticosteroid therapy in rheumatology clinical trials poses a major challenge. We describe the consensus methodology used to design an algorithm to standardize changes in corticosteroid dosing during the Randomized Placebo Phase Study of Rilonacept in Systemic Juvenile Idiopathic Arthritis Trial (RAPPORT).Methods: The 20 RAPPORT site principal investigators (PIs) and 4 topic specialists constituted an expert panel that participated in the consensus process. The panel used a modified Delphi Method consisting of an on-line questionnaire, followed by a one day face-to-face consensus conference. Consensus was defined as ≥ 75% agreement. For items deemed essential but when consensus on critical values was not achieved, simple majority vote drove the final decision.Results: The panel identified criteria for initiating or increasing corticosteroids. These included the presence or development of anemia, myocarditis, pericarditis, pleuritis, peritonitis, and either complete or incomplete macrophage activation syndrome (MAS). The panel also identified criteria for tapering corticosteroids which included absence of fever for ≥ 3 days in the previous week, absence of poor physical functioning, and seven laboratory criteria. A tapering schedule was also defined.Conclusion: The expert panel established consensus regarding corticosteroid management and an algorithm for steroid dosing that was well accepted and used by RAPPORT investigators. Developed specifically for the RAPPORT trial, further study of the algorithm is needed before recommendation for more general clinical use.

AB - Background: The management of background corticosteroid therapy in rheumatology clinical trials poses a major challenge. We describe the consensus methodology used to design an algorithm to standardize changes in corticosteroid dosing during the Randomized Placebo Phase Study of Rilonacept in Systemic Juvenile Idiopathic Arthritis Trial (RAPPORT).Methods: The 20 RAPPORT site principal investigators (PIs) and 4 topic specialists constituted an expert panel that participated in the consensus process. The panel used a modified Delphi Method consisting of an on-line questionnaire, followed by a one day face-to-face consensus conference. Consensus was defined as ≥ 75% agreement. For items deemed essential but when consensus on critical values was not achieved, simple majority vote drove the final decision.Results: The panel identified criteria for initiating or increasing corticosteroids. These included the presence or development of anemia, myocarditis, pericarditis, pleuritis, peritonitis, and either complete or incomplete macrophage activation syndrome (MAS). The panel also identified criteria for tapering corticosteroids which included absence of fever for ≥ 3 days in the previous week, absence of poor physical functioning, and seven laboratory criteria. A tapering schedule was also defined.Conclusion: The expert panel established consensus regarding corticosteroid management and an algorithm for steroid dosing that was well accepted and used by RAPPORT investigators. Developed specifically for the RAPPORT trial, further study of the algorithm is needed before recommendation for more general clinical use.

UR - http://www.scopus.com/inward/record.url?scp=84865413618&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865413618&partnerID=8YFLogxK

U2 - 10.1186/1546-0096-10-31

DO - 10.1186/1546-0096-10-31

M3 - Article

C2 - 22931206

AN - SCOPUS:84865413618

SN - 1546-0096

VL - 10

JO - Pediatric Rheumatology

JF - Pediatric Rheumatology

M1 - 31

ER -

Algorithm development for corticosteroid management in systemic juvenile idiopathic arthritis trial using consensus methodology

Abstract

Bibliographical note

Publisher link

Find It

Other files and links

Fingerprint

Cite this